Novozymes' New CEO Takes Office
News Apr 02, 2013
“I am proud and honored to lead this great company forward,” says Peder Holk Nielsen. “Novozymes is in a very strong position, and we will continue with our overall strategy. Our success rests on our ability to bring new innovation to our customers, and our ability to find new ways biotechnology can help them improve their products and make more with less. A key focus for me will be to make sure we bring these innovations to the market even faster than we do today.”
Peder Holk Nielsen, 56, has played a central role in the development of Novozymes in its current form. His 28-year career in Novozymes and Novo Industri/Novo Nordisk spans management positions across business development, research and development, quality management and sales and marketing. Up until his appointment as CEO, he served as Executive Vice President and Head of Enzyme Business from 2007-2013.
Peder Holk Nielsen takes over as CEO from Steen Riisgaard, who steps down after 12 years in the company’s top post and 33 years in Novozymes and Novo Industri/Novo Nordisk.
New executive leadership team
The appointment of Peder Holk Nielsen as Novozymes’ new CEO was announced on January 21, 2013, in connection with the company’s full year earnings report.
Novozymes’ Executive Leadership Team as of April 1, 2013:
President & CEO: Peder Holk Nielsen
Business Development: EVP Thomas Videbæk
Business Operations: EVP Andrew Fordyce
Supply Operations: EVP Thomas Nagy
Research & Development: EVP Per Falholt
Corporate Functions: EVP and CFO Benny D. Loft
The executive management is joined by Andrew Fordyce, 49, former Vice President of Sales and Customer Solutions.
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018